Inventor · disambiguated record
Chunlei Li
Also filed as: LI CHUNLEI
7 granted patents·14 pending applications·20 citations·filing 2007–2025
78Inventor score
Files withCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD13LI CHUNLEI2TRAVELERS INDEMNITY CO2WANBANG BIOPHARMACEUTICALS2CN SHENHUA COAL LIQUID & CHEM1
Top patents by PatentIndex Score
21 records- 0186US8871253B2Liposome having inner water phase containing sulfobutyl ether cyclodextrin saltLI CHUNLEI·Filed 2010·Granted Oct 28, 2014·12 cites·8 claims
- 0275US11357728B2Liposome having inner water phase containing sulfobutyl ether cyclodextrin saltCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2014·Granted Jun 14, 2022·1 cites·13 claims
- 0374US9813398B2Method and system for Internet of things capability integrationZTE CORP·Filed 2012·Granted Nov 7, 2017·5 cites·12 claims
- 0474US2025377873A1Methods for application and data dependency identification, visualization, and managementTRAVELERS INDEMNITY CO·Filed 2025·Application pending·0 cites
- 0568US10028913B2Liposomal pharmaceutical preparation and method for manufacturing the sameCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2016·Granted Jul 24, 2018·1 cites·13 claims
- 0664US11583508B2Use of mitoxantrone liposome for treating non-Hodgkin's lymphomaCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2019·Granted Feb 21, 2023·1 cites·15 claims
- 0762US2025288535A1Instant nanoparticle composition and preparation method thereforCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2023·Application pending·0 cites
- 0859US12436748B2Systems for application and data dependency identification, visualization, and managementTRAVELERS INDEMNITY CO·Filed 2023·Granted Oct 7, 2025·0 cites·27 claims
- 0957US2024269092A1Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumorsCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2022·Application pending·0 cites
- 1056US2024156774A1Stable docetaxel albumin nanoparticle compositionCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2022·Application pending·0 cites
- 1154US2024024257A1Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisoneCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1254US2024122875A1Use of mitoxantrone hydrochloride liposomeCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2022·Application pending·0 cites
- 1352US2024058280A1Use of mitoxantrone hydrochloride liposomeCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1452US2023293454A1Use of mitoxantrone hydrochloride liposome and pegaspargaseCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1551US2023078702A1Use of mitoxantrone hydrochloride liposome for treating breast cancerCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1650US2020060982A1Purified therapeutic nanoparticles and preparation methods thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2019·Application pending·0 cites
- 1749US2011002977A1Liposomal pharmaceutical preparation and method for manufacturing the sameLI CHUNLEI·Filed 2007·Application pending·0 cites
- 1844US10500165B2Purified therapeutic nanoparticles and preparation methods thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2015·Granted Dec 10, 2019·0 cites·28 claims
- 1942US2025091975A1Preparation method for sglt2 inhibitor intermediate vWANBANG BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 2042US2025178996A1Sglt2 inhibitor intermediate v-1 and use thereofWANBANG BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 2139US2025208099A1Method for determining oxalic acid content of dimethyl oxalateCN SHENHUA COAL LIQUID & CHEM·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chunlei Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →